Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pentostatin Low-Dose TBI Is an Effective Conditioning Regimen That Permits Donor Engraftment in Patients with High Co-Morbidities Undergoing the First Transplant or Prior to a Second Transplant

Ani Gvajaia, Joseph Rimando, William Blum, Colin A. Vale, Cynthia R. Giver, Elaina L. Corbett, Kevin Hall, Kristina Murphy, Mary Jo Lechowicz, Michel Conn, Minal Surati, Muna Qayed, Amelia Langston, Edmund K. Waller

Blood (2024) 144 (Supplement 1): 7325.

https://doi.org/10.1182/blood-2024-211880

Published: 2024

Journal Articles

Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis

Joseph Rimando, Michel Conn, William Blum, Jason T Romancik, Colin Vale, Amelia Langston, Edmund K. Waller, Kevin Hall

Blood (2024) 144 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2024-198921

Published: 2024

Journal Articles

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

Francesco Mazziotta, Luca Biavati, Joseph Rimando, Sergio Rutella, Nicholas Borcherding, Sonali Parbhoo, Rupkatha Mukhopadhyay, Sayan Chowdhury, Hanna A. Knaus, Peter Valent, Hubert Hackl, Ivan M. Borrello, Bruce R. Blazar, Katerina Hatzi, Ivana Gojo, Leo Luznik

Blood (2024) 144 (11): 1168–1182.

https://doi.org/10.1182/blood.2023021680

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik

Blood (2023) 142 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2023-179394

Published: 2023

Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study

Jonathan Allen Webster, Marlise R. Luskin, Joseph Rimando, Amanda Blackford, Amer M. Zeidan, Elad Sharon, Howard Streicher, Daniel J. DeAngelo, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 966.

https://doi.org/10.1182/blood-2023-191109

Published: 2023

Journal Articles

How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond

Joseph Rimando, Shannon R. McCurdy, Leo Luznik

Blood (2023) 141 (1): 49–59.

https://doi.org/10.1182/blood.2021015129

Published: 2023

Includes: Supplemental data

Journal Articles

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Francesco Mazziotta, Luca Biavati, Sonali Parbhoo, Sayan Chowdhury, Joseph Rimando, Ivan M. Borrello, Katerina Hatzi, Bruce R. Blazar, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 9132–9133.

https://doi.org/10.1182/blood-2022-167107

Published: 2022

Journal Articles

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Joseph Rimando, Leslie Cope, Karen McKinnon, Benjamin G. Vincent, Sergio Rutella, Joshua F. Zeidner, Jonathan S. Serody, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 6314–6315.

https://doi.org/10.1182/blood-2022-165458

Published: 2022

Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-133891

Published: 2020

Journal Articles

HLA Class II Epitope Mismatch Influences Relapse and Engraftment in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

Joseph Rimando, MD, Michael Slade, MD MS, Feng Gao, PhD, Rizwan Romee, MD, Chang Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2018-99-112494

Published: 2018

Journal Articles

The Relationship between HLA Disparity and Clinical Outcomes in Peripheral Blood T Cell Replete Haploidentical Hematopoietic Cell Transplantation

Joseph Rimando, BS, Michael Slade, MDMS, Feng Gao, PhD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 4555.

https://doi.org/10.1182/blood.V130.Suppl_1.4555.4555

Published: 2017

NARROW

Pentostatin Low-Dose TBI Is an Effective Conditioning Regimen That Permits Donor Engraftment in Patients with High Co-Morbidities Undergoing the First Transplant or Prior to a Second Transplant

Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study

How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

HLA Class II Epitope Mismatch Influences Relapse and Engraftment in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

The Relationship between HLA Disparity and Clinical Outcomes in Peripheral Blood T Cell Replete Haploidentical Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only